Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Collaborator: Roche Pharma AG
• Treatments: Albumin-Bound Paclitaxel; Capecitabine; Paclitaxel

Criteria

Inclusion Criteria:

1. Ambulatory males or females, aged no less than 18 years.

2. ECOG performance status: 0-1.

3. Histologically confirmed gastric adeno-carcinoma.

4. Radiologically confirmed liver metastasis without other distant metastasis.

5. No serious concomitant medical illnesses

6. Life expectancy more than 3 months

7. Be willing and able to comply with the protocol for the duration of the study

8. No Prior treatment for metastatic disease

9. Give signed informed consent

Exclusion Criteria:

1. not fit for the inclusion criteria

2. not able to comply with the protocol

3. with high risks which may compromise the benefit of proposed regimen

4. Active (significant or uncontrolled) gastrointestinal bleeding